| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Cannabis Use Disorder Treatment Market Size 2024 |
USD 1,700 Million |
| Cannabis Use Disorder Treatment Market, CAGR |
4.7% |
| Cannabis Use Disorder Treatment Market Size 2032 |
USD 2,454.83 Million |
Market Overview
The Cannabis Use Disorder Treatment Market is projected to grow from USD 1,700 million in 2024 to an estimated USD 2,454.83 million by 2032, with a compound annual growth rate (CAGR) of 4.7% from 2024 to 2032.
Key drivers of the cannabis use disorder treatment market include the rising prevalence of cannabis use disorder globally, increasing awareness about mental health, and the growing acceptance of cannabis-related treatments. As more countries legalize cannabis for medical use, there is a heightened demand for effective treatment options for those struggling with addiction. The development of new pharmacological treatments, behavioral therapies, and rehabilitation programs tailored for cannabis users is further propelling market growth. Additionally, the expansion of mental health services and government-backed initiatives aimed at providing accessible treatment options are contributing to the market’s expansion.
Regionally, North America holds a significant share of the cannabis use disorder treatment market, primarily due to the legalization of cannabis in multiple states in the U.S. and Canada, as well as the increasing number of people seeking treatment for cannabis addiction. The European market is also expected to grow significantly, driven by progressive policies and the rising acceptance of cannabis as a medical treatment. In Asia Pacific, countries such as Australia and New Zealand are witnessing an increase in demand for cannabis-related treatments, while other nations in the region are beginning to explore therapeutic cannabis options. Latin America and the Middle East & Africa regions are gradually emerging as new markets for cannabis use disorder treatment, with governments and healthcare providers working to address addiction issues in these areas.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
Download Sample
Market Insights:
- The Cannabis Use Disorder Treatment Market is expected to grow from USD 1,700 million in 2024 to USD 2,454.83 million by 2032, at a CAGR of 4.7%.
- Increasing prevalence of cannabis use disorder, rising public awareness about mental health, and greater acceptance of cannabis-related treatments drive market growth.
- The development of new pharmacological treatments, behavioral therapies, and rehabilitation programs specifically for cannabis addiction is fueling the market.
- Government initiatives, including policies supporting mental health services and addiction treatment, are contributing to the market’s expansion.
- Stigma surrounding addiction treatment, lack of standardized treatment protocols, and limited access to professional healthcare in some regions may hinder market growth.
- North America dominates the market due to cannabis legalization in several U.S. states and Canada, increasing the need for addiction treatment services.
- In Europe, Asia Pacific, and Latin America, the growing acceptance of cannabis for medical use and increasing demand for treatment options offer significant market opportunities.
Market Drivers:
Increasing Prevalence of Cannabis Use Disorder:
The rising prevalence of cannabis use disorder (CUD) continues to be a critical driver for the cannabis use disorder treatment market. In the United States alone, an estimated 9% of cannabis users will develop a dependence, with the numbers growing as cannabis use becomes more widespread. Among these individuals, around 2.5 million people suffer from cannabis use disorder and require specialized treatment. For instance, in 2021, the U.S. Department of Health and Human Services (HHS) allocated $10.7 million to support the expansion of treatment programs for cannabis-related addiction, underscoring the increasing need for effective solutions. In Europe, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reported in 2020 that nearly 7.6 million Europeans sought treatment for cannabis-related issues, reflecting the global rise in cannabis use disorder cases. This surge in demand for treatment services across various regions has created a substantial opportunity for the cannabis use disorder treatment market to grow and expand.
Advancements in Cannabis Addiction Treatment Research:
A major driver of market growth is the ongoing research into effective treatments for cannabis addiction. For instance, in 2020, the U.S. National Institutes of Health (NIH) invested more than $60 million in research aimed at understanding the neurological mechanisms of cannabis use disorder and testing new treatments. One of the key areas of focus is the use of pharmacological treatments to address withdrawal symptoms and cravings. Additionally, the FDA has awarded $15.5 million in grants to pharmaceutical companies for the development of cannabinoid-based medications aimed at treating addiction. In 2021, the NIH allocated $5.4 million to a study focusing on the use of cannabinoids like cannabidiol (CBD) to alleviate cannabis dependence. This research has already shown promising results, with early studies suggesting that CBD may reduce cannabis consumption and improve treatment outcomes.
Government Support and Policy Initiatives:
Government support plays a crucial role in driving the cannabis use disorder treatment market, particularly through funding and the implementation of targeted policies. In the United States, the Centers for Disease Control and Prevention (CDC) reports that the federal government allocated more than $1.5 billion in 2020 for addiction prevention and treatment programs, with a growing portion of that budget dedicated to cannabis use disorder treatment. Furthermore, the Substance Abuse and Mental Health Services Administration (SAMHSA) awarded $30 million in 2021 to state and local governments to develop specialized treatment programs for cannabis use disorder. For instance, the World Bank’s Health Financing Strategy 2020-2025 commits $500 million annually to improving mental health and addiction services worldwide. In addition, the World Health Organization (WHO) has outlined strategic plans to enhance mental health services in developing regions, with an emphasis on addressing substance use disorders, including cannabis addiction.
Rising Public Awareness and Acceptance of Cannabis Addiction Treatment:
Public awareness surrounding cannabis addiction is steadily increasing, particularly in regions where cannabis has been legalized. In Canada, following the legalization of recreational cannabis in 2018, the demand for cannabis-related treatment services grew. For Instance, according to the Canadian Centre on Substance Use and Addiction (CCSA), the number of individuals seeking treatment for cannabis use disorder increased by 15% in the two years following legalization. The package focuses on increasing the availability of mental health services and providing additional support for individuals struggling with cannabis addiction. This funding is intended to expand access to addiction treatment services specifically tailored for veterans and includes efforts to integrate telemedicine solutions into the treatment process, reflecting the growing trend of digital healthcare solutions in addiction treatment.
Market Trends:
Digital Health Solutions in Cannabis Use Disorder Treatment:
A growing trend in the cannabis use disorder treatment market is the integration of digital health technologies, such as telemedicine and mobile health applications, into addiction treatment programs. Governments and health organizations are increasingly embracing digital solutions to improve access to care, particularly in underserved or rural areas. For instance, The U.S. Food and Drug Administration (FDA) has recognized the role of telehealth in providing mental health services, allocating $10 million in 2021 for the development of digital tools for addiction treatment. Telemedicine platforms have gained significant traction, offering individuals remote consultations with addiction specialists, thus reducing barriers such as travel time and costs. According to the U.S. Centers for Medicare & Medicaid Services (CMS), the use of telemedicine for addiction treatment services has increased by 50% in the past two years, reflecting the growing reliance on digital solutions in addressing cannabis use disorder.
Focus on Holistic and Personalized Treatment Approaches:
There is a notable shift towards holistic and personalized treatment approaches in addressing cannabis use disorder. This trend includes a combination of behavioral therapy, pharmacological treatments, and mental health services, tailored to meet the unique needs of individuals. The U.S. National Institutes of Health (NIH) has been funding research into integrated treatment models that focus not only on treating the addiction itself but also on addressing underlying mental health issues, such as anxiety and depression, which often co-occur with cannabis use disorder. For instance, the NIH awarded $15 million in 2021 to fund studies on cognitive-behavioral therapy (CBT) combined with medication-assisted treatment (MAT) for cannabis users. This trend is further supported by the World Health Organization (WHO), which has emphasized the importance of integrated care in addressing substance use disorders, including cannabis addiction.
Public and Private Sector Collaboration:
Public and private sector collaboration is increasingly driving the development of treatment options for cannabis use disorder. Governments are working alongside pharmaceutical companies, research institutions, and non-profit organizations to develop new treatment methodologies and improve the quality of care available to individuals suffering from addiction. For instance, The U.S. National Institute on Drug Abuse (NIDA) has partnered with private biotechnology companies to test new pharmacological treatments for cannabis addiction, with $20 million allocated in 2021 for collaborative research in this area. Moreover, the World Bank has been supporting initiatives in low- and middle-income countries to strengthen mental health and addiction treatment systems, with an emphasis on public-private partnerships. These collaborations are expected to expedite the development of new treatment options and improve the accessibility of care in underserved regions.
Expansion of Legal and Regulatory Frameworks:
As the legalization of cannabis continues to expand in several regions, new regulatory frameworks are emerging that govern both the use of cannabis and the treatment of cannabis use disorder. Governments are increasingly recognizing cannabis addiction as a public health issue and are implementing new policies to ensure that effective treatment options are available. For instance, in 2022, the European Union (EU) revised its health policies to provide greater funding for addiction treatment services, including those for cannabis use disorder, with a focus on expanding healthcare access to individuals in countries where cannabis use is legal. In the U.S., the Department of Health and Human Services (HHS) has introduced new guidelines that encourage state and local governments to integrate cannabis addiction treatment into their public health programs.
Market Challenges Analysis:
Regulatory and Legal Barriers:
One of the major challenges facing the cannabis use disorder treatment market is the inconsistent regulatory landscape across different regions. While countries like Canada and several U.S. states have legalized cannabis for medical and recreational use, many other regions still face stringent laws and regulations that restrict the availability of cannabis-based treatments. For instance, in much of Europe and Asia, cannabis remains heavily regulated or illegal, which hampers the development and adoption of cannabis-related addiction therapies. This lack of uniformity creates barriers for pharmaceutical companies and healthcare providers who want to offer comprehensive treatment solutions, as regulatory approvals are often slow, expensive, and complicated. In countries where cannabis is still illegal, healthcare providers may be hesitant to offer treatment programs or may face legal risks for promoting cannabis-related addiction therapies. As a result, fragmented legal frameworks limit the accessibility and adoption of cannabis addiction treatment, hindering the market’s overall growth.
Stigma and Public Perception:
Another challenge impacting the cannabis use disorder treatment market is the persistent stigma surrounding addiction treatment and cannabis use itself. Despite the increasing legalization of cannabis in various regions, many individuals still perceive cannabis use disorder as a less serious condition compared to other forms of addiction. Public stigma can prevent people from seeking treatment due to fear of judgment or discrimination. For instance, in some parts of the United States, even though cannabis has been legalized in many states, social stigma around addiction to cannabis often deters individuals from accessing professional help. Additionally, there is a lack of widespread education regarding the severity of cannabis addiction, which leads to fewer individuals recognizing the need for specialized treatment. This societal stigma not only discourages patients from seeking care but also reduces public and private investment in developing comprehensive treatment programs, delaying the expansion of treatment options available to those in need.
Market Opportunities:
The Cannabis Use Disorder Treatment Market presents significant opportunities through innovations in treatment methods and medical advancements. As the global understanding of cannabis addiction expands, there is an increasing focus on developing targeted pharmacological treatments and personalized therapy programs. New research into cannabinoids, alongside advancements in neuroscience and addiction medicine, can lead to the creation of more effective treatment options. Additionally, the integration of digital health technologies such as telemedicine and mobile health applications offers a promising avenue for delivering accessible and scalable treatment solutions. The ongoing exploration of cannabis-based therapies for addiction treatment could unlock novel and more efficient alternatives, which are expected to stimulate market growth and attract investments from pharmaceutical and biotech companies.
Another key opportunity lies in the expanding legalization of cannabis across various regions, which is driving the demand for specialized treatment services for cannabis use disorder. As countries and states continue to legalize cannabis for medical and recreational use, the incidence of cannabis use disorder is expected to rise, creating an urgent need for effective treatment solutions. This trend opens up significant growth potential for healthcare providers, treatment centers, and pharmaceutical companies offering addiction recovery services. Moreover, emerging markets in Asia Pacific, Latin America, and Africa are beginning to explore cannabis-related treatments, which presents new avenues for market expansion. In these regions, the growing acceptance of cannabis as a medical option, coupled with evolving healthcare infrastructure, creates an environment ripe for the introduction of advanced treatment services for cannabis addiction.
Market Segmentation Analysis:
By Treatment type, which includes pharmacological treatments, behavioral therapies, and rehabilitation programs. Pharmacological treatments, including cannabinoid-based medications and other therapeutic drugs, are gaining prominence due to their ability to manage withdrawal symptoms and cravings. Behavioral therapies, such as Cognitive Behavioral Therapy (CBT) and contingency management, remain crucial for long-term recovery by addressing the psychological aspects of addiction. Rehabilitation programs, including inpatient and outpatient services, provide a structured environment for patients to undergo detoxification and recovery. These treatments are often integrated to offer comprehensive care, ensuring better recovery outcomes for individuals suffering from cannabis use disorder.
By Treatment, the market is divided into detoxification, counseling and behavioral therapy, medications, and support groups. Detoxification involves managing withdrawal symptoms and preparing patients for further treatment. Counseling and behavioral therapy, such as cognitive-behavioral therapy (CBT) and motivational enhancement therapy (MET), are essential for addressing the psychological aspects of the disorder. Medications, including synthetic cannabinoids and CB1 receptor antagonists, are being explored as potential treatments. Support groups provide a community-based approach to recovery, offering peer support and shared experiences.
By End User, the market encompasses hospitals and clinics, rehabilitation centers, and other settings. Hospitals and clinics provide comprehensive treatment options, including medical and psychological care. Rehabilitation centers offer specialized programs for individuals with severe cannabis use disorder, focusing on long-term recovery and relapse prevention. Other settings, such as community health centers and private practices, also play a role in providing treatment and support.
Segmentations:
By Type:
- Pharmacological treatments
- Behavioral therapies
- Rehabilitation programs
- Others
By Treatment:
- Detoxification
- Counselling & Behavioral Therapy
- Medication
- Support Group
By End User:
- Hospitals and Clinics
- Rehabilitation Centers
- Others
Based on Region:
- North America
- Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Asia Pacific
- Australia
- New Zealand
- Japan
- South Korea
- India
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- United Arab Emirates
- Saudi Arabia
- Egypt
Regional Analysis:
North America
North America holds the largest market share in the cannabis use disorder treatment market, accounting for approximately 40% of the total market share. This is primarily driven by the widespread legalization of cannabis in the United States and Canada, both for medical and recreational use. As cannabis becomes more accessible, the need for effective treatment options for cannabis use disorder has significantly increased. The U.S. has seen a surge in cannabis-related treatment services, with numerous states implementing programs to support individuals struggling with cannabis addiction. The support from government-backed initiatives, such as funding from the U.S. Department of Health and Human Services (HHS) and the National Institute on Drug Abuse (NIDA), has further contributed to market growth. In addition, the integration of telemedicine and digital health tools has allowed individuals to access cannabis addiction treatments remotely, making healthcare more accessible. This region will continue to dominate the market due to the ongoing expansion of both cannabis usage and treatment facilities, as well as the steady demand for integrated care that combines pharmacological treatments with behavioral therapies.
Europe
Europe is the second-largest market for cannabis use disorder treatment, holding approximately 30% of the market share. The region’s growth is driven by progressive policies and increasing acceptance of cannabis as a medical treatment, especially in countries such as Germany, the United Kingdom, and France. Legalization of medical cannabis has led to an increased need for specialized treatment services for individuals dealing with cannabis use disorder. In the U.K., cannabis treatment programs are being expanded in line with national health strategies to address substance abuse disorders. Several European countries, including Italy, Spain, and the Netherlands, have also seen a rise in demand for addiction treatment services. Moreover, the European Union’s health policies have promoted funding for mental health and addiction treatment programs, including cannabis use disorder, which has created a favorable environment for market expansion. As governments continue to invest in mental health initiatives, the demand for both outpatient and inpatient services is expected to rise.
Asia Pacific
Asia Pacific is one of the fastest-growing regions in the cannabis use disorder treatment market, currently holding around 20% of the global market share. The region’s growth is driven by the increasing recognition of cannabis use disorder as a public health concern and the growing acceptance of medical cannabis in countries like Australia and New Zealand. Australia, in particular, has made significant strides in legalizing medical cannabis and providing comprehensive treatment programs for patients struggling with cannabis dependence. In New Zealand, cannabis use for medicinal purposes has become more widely accepted, prompting the need for specialized addiction services. While other countries in Asia, such as Japan, South Korea, and India, are still in early stages of cannabis legalization and regulation, the demand for cannabis-related addiction treatments is beginning to gain attention. In India, the government has acknowledged the need for better addiction treatment programs, especially for substance use disorders, which may eventually include cannabis. Despite challenges posed by stricter regulations in some countries, the growing interest in cannabis-based treatments is expected to drive future market growth in the region.
Latin America and Middle East & Africa
While Latin America and the Middle East & Africa currently hold a smaller market share—around 10% collectively—both regions are emerging as potential growth markets for cannabis use disorder treatment. In Latin America, countries like Brazil and Argentina are gradually expanding their acceptance of medical cannabis, creating opportunities for treatment programs. In the Middle East and Africa, while cannabis remains largely illegal in most countries, there is a growing interest in exploring therapeutic cannabis use, particularly for medical purposes. Countries such as South Africa and the United Arab Emirates have started to make strides toward medical cannabis legalization, and in the coming years, the demand for addiction treatment services may increase as public awareness and regulatory environments evolve.
Key Player Analysis:
- Orexo AB
- Indivior PLC
- Emergent BioSolutions Inc.
- Jazz Pharmaceuticals
- Medtronic
- Kerr Corporation
- Alkermes PLC
- Teva Pharmaceutical Industries Ltd.
- AstraZeneca
- Meda Pharma (Mylan)
Competitive Analysis:
The cannabis use disorder treatment market is competitive, with numerous key players and stakeholders vying for dominance as the demand for addiction treatment grows globally. Pharmaceutical companies are at the forefront, developing cannabinoid-based medications and other pharmacological treatments specifically designed for cannabis use disorder. Companies like GW Pharmaceuticals, known for its work in developing CBD-based therapies, and Tilray, a major player in the cannabis industry, have made significant strides in creating products that target cannabis addiction. Additionally, a growing number of behavioral health service providers and rehabilitation centers are focusing on providing evidence-based therapies, such as cognitive-behavioral therapy (CBT) and contingency management, to cater to the psychological aspects of cannabis addiction. While the market is mainly driven by large healthcare providers and pharmaceutical companies, startups and research institutions are also making inroads by developing innovative digital health solutions, such as telemedicine platforms and mobile health applications, to offer remote addiction treatment. The National Institute on Drug Abuse (NIDA) and World Health Organization (WHO) have collaborated with research organizations to improve treatment protocols and advance understanding of cannabis addiction, further fueling innovation in the market. Despite the rapid advancements in treatment offerings, the market faces challenges related to fragmented regulatory frameworks and varying levels of public acceptance. As such, the competition will intensify as companies aim to navigate regulatory hurdles while expanding their product portfolios to include more personalized, integrated treatment options that address the multifaceted nature of cannabis use disorder.
Recent Developments:
- Orexo AB (August 2024): Orexo AB announced the successful completion of a human pharmacokinetic study for its OX125 intranasal nalmefene product, designed to address opioid overdose in rural areas. This innovation reflects Orexo’s broader commitment to developing rescue medications that could potentially be adapted for cannabis use disorder treatment, particularly in cases requiring fast-acting solutions.
- Indivior PLC (September 2024): Indivior provided an update on Aelis Farma’s Phase 2B clinical trial for AEF0117, a novel treatment for cannabis use disorder (CUD). However, the trial did not meet its primary and secondary endpoints, and Indivior does not currently expect to exercise its option for AEF0117.
- Emergent BioSolutions Inc. (2023): Emergent BioSolutions expanded its focus on addiction treatments by exploring the repurposing of existing pharmacotherapies for cannabis use disorder. The company emphasized the importance of combining pharmacotherapy with psychotherapy to enhance treatment outcomes and address unmet public health needs in managing CUD.
- Jazz Pharmaceuticals (December 2024): Jazz Pharmaceuticals presented real-world evidence at the American Epilepsy Society Annual Meeting showcasing the broad-spectrum efficacy of Epidiolex® (cannabidiol) in treating behavioral symptoms associated with neurological disorders. These findings reinforce the potential of cannabidiol-based therapies in addressing cannabis use disorder by leveraging its neuroprotective and behavioral benefits.
Market Concentration & Characteristics:
The cannabis use disorder treatment market exhibits a moderate level of concentration, with a mix of large pharmaceutical companies, healthcare providers, and emerging players focused on specialized treatments. Major pharmaceutical companies, such as GW Pharmaceuticals, AbbVie, and Tilray, dominate the market by developing and commercializing cannabinoid-based medications, which have gained regulatory approval in certain regions for treating addiction-related conditions. These companies are increasingly expanding their portfolios to include treatments specifically targeting cannabis use disorder. In addition to large corporations, mental health clinics, rehabilitation centers, and digital health platforms are vital players, focusing on behavioral therapies and telehealth services to cater to patients with cannabis use disorder. Startups and smaller players are leveraging innovations in technology, such as mobile health applications, virtual recovery programs, and artificial intelligence-driven monitoring tools, to provide personalized and remote treatment options. The market is characterized by a high degree of innovation, with continuous research and clinical trials aimed at developing more effective pharmacological treatments and therapy programs. However, the market’s fragmented nature—due to varying levels of cannabis legalization and regulatory approval across regions—means that competition is uneven across geographical areas. North America leads the market, while regions like Asia Pacific, Latin America, and the Middle East & Africa are emerging markets with untapped potential. Additionally, the market is witnessing increasing collaboration between pharmaceutical companies, governments, and healthcare institutions, especially as public awareness of cannabis use disorder rises. This cooperative dynamic is shaping the market, pushing for more integrated and comprehensive treatment solutions.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Report Coverage:
The research report offers an in-depth analysis based on By Type, By Treatment and By Treatment. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook:
- The Cannabis Use Disorder Treatment Market will continue to expand as the global prevalence of cannabis use disorder increases due to greater cannabis consumption and legalization trends.
- Increased awareness of mental health and addiction treatment will drive demand for more specialized services, including both pharmacological and behavioral therapies for cannabis users.
- Advancements in treatment options, including the development of cannabinoid-based medications and cognitive-behavioral therapies.
- The expansion of telemedicine and digital health solutions will increase access to treatment.
- Governments worldwide will continue to enhance funding for mental health and addiction services.
- The rising number of countries legalizing cannabis, particularly in North America, Europe, and parts of Asia Pacific.
- Regional variations in cannabis legalization will create diverse opportunities for market growth, with new markets emerging in Latin America and the Middle East & Africa.
- Collaboration between pharmaceutical companies, healthcare providers, and government bodies will accelerate the development and accessibility of effective treatment programs.
- Growing public acceptance and reduced stigma around addiction treatment will encourage more individuals to seek professional help for cannabis use disorder.
- The ongoing research and clinical trials into cannabis addiction therapies will lead to more innovative solutions and improved treatment efficacy in the coming years.
